Monte Rosa Therapeutics, Inc. - GLUE STOCK NEWS

Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company focused on developing molecular glue degrader (MGD)-based medicines, has announced its participation in the Jefferies London Healthcare Conference. CEO Markus Warmuth will engage in a fireside chat on November 19, 2024, at 4:00 p.m. GMT. The presentation will be available through webcast in the 'Events' section of Monte Rosa's website, with recordings accessible for 30 days after the event.

Monte Rosa Therapeutics announced Q3 2024 financial results and significant developments. The company secured a global license agreement with Novartis for VAV1-directed molecular glue degraders, including MRT-6160, receiving $150M upfront with potential for $2.1B in milestones. Key clinical programs include MRT-2359 for MYC-driven tumors with results expected year-end, and MRT-8102 targeting IL-1β with IND filing planned for H1 2025. Q3 financial results showed revenue of $9.2M and net loss of $23.9M. With the Novartis deal, cash runway extends into 2028.

Monte Rosa Therapeutics (Nasdaq: GLUE) has entered a global exclusive license agreement with Novartis for VAV1 molecular glue degraders (MGDs), including MRT-6160. The deal includes a $150 million upfront payment and potential milestone payments up to $2.1 billion.

Under the agreement, Novartis gains worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs, taking responsibility for Phase 2 clinical studies onwards. Monte Rosa will complete the ongoing Phase 1 study, share U.S. profits/losses, and receive tiered royalties on ex-U.S. sales. MRT-6160 is currently in Phase 1 trials for immune-mediated conditions.

Monte Rosa Therapeutics presented preclinical data on its cyclin E1-directed molecular glue degraders (MGDs) at the 36th EORTC-NCI-AACR Symposium. The company's MGD compound, MRT-50969, demonstrated selective degradation of cyclin E1 in CCNE1-amplified solid tumors. The drug showed promising results in preclinical trials, including tumor growth suppression and regression in breast and gastric cancer models. Unlike CDK2 inhibitors, MRT-50969 exhibited higher selectivity and RB-dependent inhibition. The research revealed a new binding mechanism through cryo-EM analysis, suggesting broader applications for cereblon-based MGDs.

Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader (MGD)-based medicines, has announced its participation in two upcoming investor conferences:

1. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 4, 2024.

2. 2024 Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024, where CEO Markus Warmuth, M.D., will participate in a fireside chat at 2:15 p.m. ET.

The fireside chat will be webcast and accessible through Monte Rosa's website, with an archived version available for 30 days after the presentation.

Monte Rosa Therapeutics (Nasdaq: GLUE) has initiated a Phase 1 clinical study for MRT-6160, a novel VAV1-directed molecular glue degrader (MGD) designed to treat systemic and neurological autoimmune diseases. The first participants have been dosed in the single ascending dose / multiple ascending dose (SAD/MAD) study involving healthy volunteers. Initial results, including biomarker data demonstrating pharmacodynamic effects, are expected in Q1 2025.

MRT-6160 is a potent, highly selective, and orally bioavailable MGD that targets VAV1, a key regulator of T- and B-cell receptor activity. Preclinical data suggest potential efficacy in various autoimmune and inflammatory conditions, including inflammatory bowel disease, rheumatoid arthritis, and multiple sclerosis. The company plans to initiate proof-of-concept studies in ulcerative colitis and rheumatoid arthritis following the Phase 1 results.

Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q2 2024 financial results and corporate updates. Key highlights include:

• IND clearance for MRT-6160, a VAV1-directed MGD for autoimmune diseases
• Ongoing Phase 1/2 study of MRT-2359 for MYC-driven solid tumors
• Achievement of first milestones in Roche collaboration
• Strong cash position of $267.1 million, expected to fund operations into H1 2027

Financial results: $4.7 million in collaboration revenue, $28.1 million in R&D expenses, $9.3 million in G&A expenses, and a net loss of $30.3 million for Q2 2024. The company anticipates multiple clinical readouts and milestones in the coming years.

Monte Rosa Therapeutics, a clinical-stage biotechnology company listed on Nasdaq under the symbol GLUE, has announced that its CEO, Markus Warmuth, M.D., will participate in a fireside chat at the virtual UBS Targeted Protein Degradation Day. The event is scheduled for Monday, July 15, 2024, at 3:30 p.m. ET. The presentation will be available via a webcast on Monte Rosa's website and an archived version will be accessible for 30 days post-event.

Monte Rosa Therapeutics (Nasdaq: GLUE) announced progress updates on its two key programs, MRT-2359 and MRT-6160. The ongoing Phase 1/2 study of MRT-2359 for MYC-driven solid tumors shows favorable safety and pharmacodynamic profiles at 0.5 mg with a 21/7 dosing schedule. They are now assessing a 0.75 mg dose, with Phase 2 dose recommendations and updated results expected in H2 2024. Furthermore, an IND submission for MRT-6160, targeting autoimmune diseases, was achieved. A Phase 1 SAD/MAD study will commence this summer, with initial clinical data expected in Q1 2025.